MorphoSys (MOR) Given a €114.00 Price Target at Goldman Sachs Group

Goldman Sachs Group set a €114.00 ($132.56) price objective on MorphoSys (ETR:MOR) in a research note published on Friday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other analysts have also recently issued reports on the company. Berenberg Bank set a €108.00 ($125.58) price objective on MorphoSys and gave the company a buy rating in a research note on Wednesday, May 15th. Deutsche Bank set a €125.00 ($145.35) price objective on MorphoSys and gave the company a buy rating in a research note on Thursday, May 9th. Independent Research set a €96.00 ($111.63) price objective on MorphoSys and gave the company a neutral rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on MorphoSys and gave the company a buy rating in a research note on Wednesday, May 8th. Finally, Royal Bank of Canada set a €65.00 ($75.58) price objective on MorphoSys and gave the company a sell rating in a research note on Thursday, March 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of €100.78 ($117.18).

Shares of ETR MOR opened at €93.30 ($108.49) on Friday. The firm has a market capitalization of $2.95 billion and a PE ratio of -50.22. The company has a debt-to-equity ratio of 8.65, a quick ratio of 7.53 and a current ratio of 7.75. MorphoSys has a 12-month low of €76.45 ($88.90) and a 12-month high of €124.90 ($145.23).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

See Also: Moving Average (MA)

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.